GleamWall
中文EN

ALXO ALX ONCOLOGY HOLDINGS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1810182 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY25.4%
TTM EPS YoY56.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-94.4%
ROA-67.9%
ROIC (approx.)-99.6%
Asset turnover—

Leverage & solvency

Liabilities / assets18.6%
Debt / equity0.08x
Current ratio8.04x
Interest coverage-67.78x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$17.46M$13.14M$13.61M$17.64M$17.44M$18.02M$23.89M$23.53M
SG&A expense$5.48M$5.13M$5.36M$5.38M$5.09M$5.45M$7.93M$7.08M
Operating income-$22.95M-$18.03M-$18.97M-$23.02M-$22.53M-$26.65M-$31.82M-$30.61M
Interest expense$225,000$285,000$331,000$383,000$408,000$405,000$406,000$427,000
Net income-$21.83M-$17.97M-$17.93M-$22.85M-$22.14M-$25.95M-$30.75M-$29.16M
EBITDA-$22.85M-$17.93M-$18.82M-$22.87M-$22.33M-$26.45M-$31.61M-$30.40M
EPS (basic)-0.15-0.13-0.17—-0.41-0.49-0.58—
EPS (diluted)-0.15-0.13-0.17—-0.41-0.49-0.58—
Weighted avg. shares (diluted)140.90M135.64M104.57M—53.58M53.45M53.36M—
Balance sheet
Cash & equivalents$35.45M$22.69M$32.28M$16.37M$23.44M$19.30M$20.61M$17.63M
Short-term investments$111.75M$115.54M$108.04M$28.42M$37.18M$60.01M$77.22M$110.19M
Current assets$152.87M$143.46M$145.56M$50.73M$66.52M$85.26M$102.53M$134.35M
PP&E, net$149,000$166,000$1.05M$1.20M$1.35M$1.50M$2.70M$2.90M
Total assets$154.67M$160.82M$178.33M$59.05M$82.72M$95.32M$120.90M$147.78M
Current liabilities$19.02M$14.78M$20.18M$24.55M$27.72M$18.85M$18.74M$18.50M
Short-term debt$0$0$5.22M$5.22M$4.35M$3.04M$1.74M$435,000
Long-term debt$9.74M$9.71M$3.29M$4.53M$5.76M$7.00M$8.23M$9.47M
Total debt$9.74M$9.71M$8.51M$9.75M$10.11M$10.04M$9.97M$9.90M
Total liabilities$28.82M$24.63M$26.98M$33.06M$37.92M$30.91M$32.60M$34.16M
Shareholders' equity$125.85M$136.19M$151.35M$25.98M$44.80M$64.42M$88.30M$113.62M
Net debt-$25.71M-$12.98M-$23.77M-$6.62M-$13.33M-$9.26M-$10.64M-$7.73M
Shares outstanding142.63M138.22M138.22M54.39M53.58M53.51M53.38M53.05M
Cash flow statement
Operating cash flow-$14.74M-$16.06M-$18.65M-$18.98M-$17.09M-$23.41M-$24.66M-$32.05M
Capital expenditure$65,000$17,000$50,000$49,000$56,000$47,000$60,000$60,000
Free cash flow-$14.80M-$16.07M-$18.70M-$19.03M-$17.15M-$23.45M-$24.72M-$32.11M
Investing cash flow$19.24M$6.52M-$105.04M$11.23M$21.39M$22.32M$27.64M$33.18M
Financing cash flow$8.20M$137,000$139.59M$678,000-$159,000-$222,000$65,000$328,000
Depreciation & amortization$100,000$100,000$150,000$151,000$200,000$200,000$211,000$214,000
Stock-based compensation$2.89M$2.68M$2.51M$2.71M$2.52M$2.14M$5.22M$5.86M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.